VA 111913

Drug Profile

VA 111913

Alternative Names: VA 111913 TS; VA 913; VA111913

Latest Information Update: 25 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vantia Therapeutics
  • Class Small molecules
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dysmenorrhoea

Most Recent Events

  • 25 Aug 2015 No recent reports on development identified - Phase-II for Dysmenorrhoea in USA and United Kingdom (PO)
  • 15 Nov 2010 Vantia completes a phase II trial in dysmenorrhoea in USA and United Kingdom
  • 07 Oct 2009 Phase-II clinical trials in Dysmenorrhoea in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top